MedPath

乐普制药科技有限公司

Ownership
-
Established
2016-12-29
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

16

NMPA:16

Drug Approvals

Epalrestat Tablets

Product Name
依帕司他片
Approval Number
国药准字H20253534
Approval Date
Mar 4, 2025
NMPA

Ursodeoxycholic Acid Capsules

Product Name
熊去氧胆酸胶囊
Approval Number
国药准字H20249393
Approval Date
Nov 15, 2024
NMPA

Ritonavir Tablets

Product Name
利托那韦片
Approval Number
国药准字H20244170
Approval Date
Jun 28, 2024
NMPA

Oseltamivir Phosphate for Suspension

Product Name
磷酸奥司他韦干混悬剂
Approval Number
国药准字H20243080
Approval Date
Jan 23, 2024
NMPA

Doxazosin Mesylate Extended Release Tablets

Product Name
甲磺酸多沙唑嗪缓释片
Approval Number
国药准字H20233964
Approval Date
Sep 28, 2023
NMPA

Tofacitinib Citrate Sustained-release Tablets

Product Name
枸橼酸托法替布缓释片
Approval Number
国药准字H20234125
Approval Date
Sep 5, 2023
NMPA

Rosuvastatin Calcium Tablets

Product Name
瑞舒伐他汀钙片
Approval Number
国药准字H20233778
Approval Date
Jun 27, 2023
NMPA

Atorvastatin Calcium Tablets

Product Name
阿托伐他汀钙片
Approval Number
国药准字H20163270
Approval Date
Nov 28, 2022
NMPA

Atorvastatin Calcium Tablets

Product Name
阿托伐他汀钙片
Approval Number
国药准字H20133127
Approval Date
Nov 14, 2022
NMPA

Sitagliptin Phosphate Tablets

Product Name
磷酸西格列汀片
Approval Number
国药准字H20223235
Approval Date
Apr 19, 2022
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found
© Copyright 2025. All Rights Reserved by MedPath